+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Ruxolitinib"

Essential Thrombocythemia Drug Global Market Insights 2022, Analysis and Forecast to 2027, by Manufacturers, Regions, Technology, Application, Product Type - Product Thumbnail Image

Essential Thrombocythemia Drug Global Market Insights 2022, Analysis and Forecast to 2027, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • April 2022
  • 85 Pages
  • Global
From
Loading Indicator

Ruxolitinib is a type of hematological drug used to treat myelofibrosis, a type of bone marrow disorder. It works by blocking certain proteins that cause inflammation and scarring in the bone marrow. Ruxolitinib is also used to treat polycythemia vera, a rare blood disorder. It is taken orally and is available in both tablet and liquid form. Ruxolitinib is a relatively new drug, having been approved by the US Food and Drug Administration in 2011. It is the first and only approved Janus kinase (JAK) inhibitor for the treatment of myelofibrosis. It has been shown to reduce symptoms of the disease, such as enlarged spleen, fatigue, and night sweats. The ruxolitinib market is growing rapidly, with more and more patients being prescribed the drug. It is becoming increasingly popular due to its effectiveness and safety profile. Some companies in the ruxolitinib market include Incyte Corporation, Novartis, and Pfizer. Show Less Read more